197 related articles for article (PubMed ID: 31169364)
1. Immune mechanisms and possible immune therapy in testicular germ cell tumours.
Chovanec M; Mardiak J; Mego M
Andrology; 2019 Jul; 7(4):479-486. PubMed ID: 31169364
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy: last bullet in platinum refractory germ cell testicular cancer.
Semaan A; Haddad FG; Eid R; Kourie HR; Nemr E
Future Oncol; 2019 Feb; 15(5):533-541. PubMed ID: 30624089
[TBL] [Abstract][Full Text] [Related]
3. Managing seminomatous and nonseminomatous germ cell tumors.
Chahoud J; Zhang M; Shah A; Lin SH; Pisters LL; Tu SM
Curr Opin Oncol; 2018 May; 30(3):181-188. PubMed ID: 29538040
[TBL] [Abstract][Full Text] [Related]
4. Promising novel therapies for relapsed and refractory testicular germ cell tumors.
Kozakova K; Mego M; Cheng L; Chovanec M
Expert Rev Anticancer Ther; 2021 Jan; 21(1):53-69. PubMed ID: 33138660
[TBL] [Abstract][Full Text] [Related]
5. Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors.
Shah S; Ward JE; Bao R; Hall CR; Brockstein BE; Luke JJ
Cancer Immunol Res; 2016 Nov; 4(11):903-909. PubMed ID: 27638840
[TBL] [Abstract][Full Text] [Related]
6. New insights into germ cell tumor genomics.
Lafin JT; Bagrodia A; Woldu S; Amatruda JF
Andrology; 2019 Jul; 7(4):507-515. PubMed ID: 30896089
[TBL] [Abstract][Full Text] [Related]
7. Investigational targeted therapies for the treatment of testicular germ cell tumors.
Oing C; Kollmannsberger C; Oechsle K; Bokemeyer C
Expert Opin Investig Drugs; 2016 Sep; 25(9):1033-43. PubMed ID: 27286362
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206.
Adra N; Einhorn LH; Althouse SK; Ammakkanavar NR; Musapatika D; Albany C; Vaughn D; Hanna NH
Ann Oncol; 2018 Jan; 29(1):209-214. PubMed ID: 29045540
[TBL] [Abstract][Full Text] [Related]
9. Challenging presentations of germ cell tumours in routine clinical practice.
Bezawada N; Norton A; Mactier K; MacDonald G; Waterston A; Mmeka W; Malik J; Law A; Barrie C; Drummond A; Muir C; White J
J R Coll Physicians Edinb; 2021 Mar; 51(1):53-57. PubMed ID: 33877136
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of testicular cancer].
Droz JP; Boyle H; Culine S; Fizazi K; Fléchon A; Massard C
Bull Cancer; 2013 Dec; 100(12):1319-32. PubMed ID: 24316884
[TBL] [Abstract][Full Text] [Related]
11. Contralateral biopsies in patients with testicular germ cell tumours: patterns of care in Germany and recent data regarding prevalence and treatment of testicular intra-epithelial neoplasia.
Ruf CG; Gnoss A; Hartmann M; Matthies C; Anheuser P; Loy V; Pichlmeier U; Dieckmann KP
Andrology; 2015 Jan; 3(1):92-8. PubMed ID: 25146646
[TBL] [Abstract][Full Text] [Related]
12. Durable Response to Immune Checkpoint Blockade in a Platinum-Refractory Patient With Nonseminomatous Germ Cell Tumor.
Chi EA; Schweizer MT
Clin Genitourin Cancer; 2017 Oct; 15(5):e855-e857. PubMed ID: 28465048
[No Abstract] [Full Text] [Related]
13. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
Cierna Z; Mego M; Miskovska V; Machalekova K; Chovanec M; Svetlovska D; Hainova K; Rejlekova K; Macak D; Spanik S; Ondrus D; Kajo K; Mardiak J; Babal P
Ann Oncol; 2016 Feb; 27(2):300-5. PubMed ID: 26598537
[TBL] [Abstract][Full Text] [Related]
14. [What does the oncologist need from the pathologist in testicular cancer?].
Oing C; Peters MC; Bremmer F
Pathologe; 2020 Dec; 41(Suppl 2):111-117. PubMed ID: 33263812
[TBL] [Abstract][Full Text] [Related]
15. Contemporary management of postchemotherapy testis cancer.
Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
[TBL] [Abstract][Full Text] [Related]
16. Systemic immune-inflammation index in germ-cell tumours.
Chovanec M; Cierna Z; Miskovska V; Machalekova K; Kalavska K; Rejlekova K; Svetlovska D; Macak D; Spanik S; Kajo K; Babal P; De Giorgi U; Mego M; Mardiak J
Br J Cancer; 2018 Mar; 118(6):831-838. PubMed ID: 29485980
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors.
Schepisi G; Gianni C; Cursano MC; Gallà V; Menna C; Casadei C; Bleve S; Lolli C; Martinelli G; Rosti G; De Giorgi U
Front Immunol; 2023; 14():1118610. PubMed ID: 36860862
[TBL] [Abstract][Full Text] [Related]
18. Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy.
Fankhauser CD; Sander S; Roth L; Gross O; Eberli D; Sulser T; Seifert B; Beyer J; Hermanns T
Br J Cancer; 2018 Mar; 118(6):825-830. PubMed ID: 29485982
[TBL] [Abstract][Full Text] [Related]
19. Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.
Chovanec M; Cierna Z; Miskovska V; Machalekova K; Svetlovska D; Kalavska K; Rejlekova K; Spanik S; Kajo K; Babal P; Mardiak J; Mego M
Oncotarget; 2017 Mar; 8(13):21794-21805. PubMed ID: 28423520
[TBL] [Abstract][Full Text] [Related]
20. Current Management of Refractory Germ Cell Tumors and Future Directions.
Allen JC; Kirschner A; Scarpato KR; Morgans AK
Curr Oncol Rep; 2017 Feb; 19(2):8. PubMed ID: 28220447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
